Exclusive Summary

• Entecavir 0.5mg is a first-line treatment for Hepatitis B, with vast and stable global market demand, particularly in high-prevalence areas like Asia and Africa.
• The original patent has expired for many years, leading to a mature global generic market, presenting clear commercialization opportunities for new entrants, especially in underserviced regions.
• The product's inclusion in the WHO Essential Medicines List and its recommendation in international guidelines as a preferred treatment underscores its proven clinical value and widespread market acceptance.
• Generic Entecavir offers significant cost advantages, reducing treatment burdens, which is highly appealing to countries with limited healthcare budgets.
• Chinese manufacturers with international certifications and registration experience can leverage quality and compliance as competitive advantages, fostering trust with overseas partners.